UAB Digital Repository of Documents 2 records found  Search took 0.01 seconds. 
1.
12 p, 5.0 MB Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies / Vicario, Rocío (Vall d'Hebron Institut d'Oncologia) ; Peg, Vicente (Hospital Universitari Vall d'Hebron) ; Morancho, Beatriz (Vall d'Hebron Institut d'Oncologia) ; Zacarías-Fluck, Mariano F (Vall d'Hebron Institut d'Oncologia) ; Zhang, Junjie (Vall d'Hebron Institut d'Oncologia) ; Martínez-Barriocanal, Águeda (Vall d'Hebron Institut d'Oncologia) ; Navarro Jiménez, Alexandra (Hospital Universitari Vall d'Hebron) ; Aura, Claudia (Vall d'Hebron Institut d'Oncologia) ; Burgués, Octavio (Hospital Clínic Universitari (València)) ; Lluch, Ana (Hospital Clínic Universitari (València)) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Rubio, Isabel T. (Vall d'Hebron Institut d'Oncologia) ; Marangoni, Elisabetta (Institut Curie) ; Deeds, James (Novartis Oncology Translational Research (Estats Units d'Amèrica)) ; Boehm, Markus (Novartis Pharma AG (Suïssa)) ; Schlegel, Robert (Novartis Oncology Translational Research (Estats Units d'Amèrica)) ; Boehm, Markus (Novartis Pharma AG (Suïssa)) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Mosher, Rebecca (Novartis Oncology Translational Research (Estats Units d'Amèrica)) ; Boehm, Markus (Novartis Pharma (Suïssa)) ; Arribas, Joaquín V (Institució Catalana de Recerca i Estudis Avançats) ; Universitat Autònoma de Barcelona
A chromosomal region that includes the gene encoding HER2, a receptor tyrosine kinase (RTK), is amplified in 20% of breast cancers. Although these tumors tend to respond to drugs directed against HER2, they frequently become resistant and resume their malignant progression. [...]
2015 - 10.1371/journal.pone.0129876
PloS one, Vol. 10 (june 2015)  
2.
123 p, 2.1 MB Mechanisms of resistance to T-DM1 in HER2-positive breast cancer / Zhang, Junjie ; Arribas, Joaquín V., (Vicente) dir. ; Rodilla Benito, Verónica, dir. ; Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular
El cáncer de mama HER2-positivo representa alrededor del 15-30% del total de pacientes con cáncer de mama. Este subtipo tiene un mal pronóstico, seguido del subtipo Triple-negativo (TNBC), que lo tiene aún peor. [...]
HER2-positive breast cancer represents around 15-30% of the breast cancer patients. This breast cancer subtype has poor prognosis, followed by the triple negative subtype, which has the worse. Several drugs are currently approved for HER2-positive breast cancer, such as Trastuzumab, Lapatinib and T-DM1. [...]

[Bellaterra] : Universitat Autònoma de Barcelona, 2018.  

See also: similar author names
235 Zhang, J.
1 Zhang, Jennifer
1 Zhang, Jiahui
3 Zhang, Jian
1 Zhang, Jian-ye
1 Zhang, Jianbo
1 Zhang, Jianhua
1 Zhang, Jianing
1 Zhang, Jianrong
1 Zhang, Jiaqi
1 Zhang, Jiashan
1 Zhang, Jie
2 Zhang, Jieting
1 Zhang, Jieyu
2 Zhang, Jifeng
11 Zhang, Jin
1 Zhang, JinTao
1 Zhang, Jinbao
1 Zhang, Jincan
8 Zhang, Jing
1 Zhang, Jingya
2 Zhang, Jinlong
3 Zhang, Jinya
1 Zhang, Jisheng
1 Zhang, Jun
1 Zhang, Jun Y.
3 Zhang, Junda
1 Zhang, Junjun
1 Zhang, Junqiang
3 Zhang, Junsong
1 Zhang, Junyi
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.